Subscribe To
INBX / Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates
INBX News
By Seeking Alpha
August 17, 2023
Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much
INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatme more_horizontal
By Zacks Investment Research
May 4, 2023
Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate rev more_horizontal
By Zacks Investment Research
March 6, 2023
Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers more_horizontal
By PRNewsWire
November 18, 2022
Inhibrx Announces Participation in Upcoming Investor Conference
SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of the more_horizontal
By Zacks Investment Research
August 8, 2022
Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -15.48% and 21%, respectively, for the quarter ended June 2022. Do the numbers hold c more_horizontal
By Zacks Investment Research
May 3, 2022
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate rev more_horizontal